ÂÜÀòÂÒÂ×

John H. Johnson is the current CEO and Director at Reaction Biology. John has also previously held positions at Xeris Pharmaceuticals, Inc., Autolus Ltd., axogen, Verastem Oncology, and BioAgilytix. From November 2018 to December 2021, they served as a Board Member at BioAgilytix. From April 2017 to June 2019, they served as a Board Member at W2O Group. From March 2015 to October 2021, they served as the Chief Executive Officer at Strongbridge Biopharma plc. And from March 2014 to July 2020, they served as a Board Member at Portola Pharmaceuticals.

John H. Johnson received a Bachelor of Science from East Stroudsburg University of Pennsylvania. John then attended the University of Rochester - Simon Business School and the University of Pittsburgh.

Some individuals on their team include Holger Weber - Head of In Vivo Pharmacology, Project Management & Internal Innovations., Robert Hartman - Chief Information Officer, and Rebecca Eells - Director of Biophysics.